Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02291874

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02291874
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02291874. Allocation not applicable; no masking; primary purpose treatment. Start 2014-10-08 (actual); primary completion 2016-07-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ipragliflozin
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct02291874
Content hash
c3f1d0fe51d9bf6eaa3397c57d250c95295f1ac8c8ac35d01c4521249804e342